293 related articles for article (PubMed ID: 18759282)
1. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.
Pagnoux C; Hogan SL; Chin H; Jennette JC; Falk RJ; Guillevin L; Nachman PH
Arthritis Rheum; 2008 Sep; 58(9):2908-18. PubMed ID: 18759282
[TBL] [Abstract][Full Text] [Related]
2. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.
Hogan SL; Falk RJ; Chin H; Cai J; Jennette CE; Jennette JC; Nachman PH
Ann Intern Med; 2005 Nov; 143(9):621-31. PubMed ID: 16263884
[TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease.
Cao Y; Tian Z; Li W; Ma L; Yu Y; Ren W
J Rheumatol; 2014 May; 41(5):916-22. PubMed ID: 24634200
[TBL] [Abstract][Full Text] [Related]
4. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
5. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center.
Li ZY; Chang DY; Zhao MH; Chen M
Arthritis Rheumatol; 2014 Jul; 66(7):1920-6. PubMed ID: 24623469
[TBL] [Abstract][Full Text] [Related]
6. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
8. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
9. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
Front Immunol; 2020; 11():2053. PubMed ID: 33013868
[No Abstract] [Full Text] [Related]
11. Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse.
Yamaguchi M; Ando M; Kato S; Katsuno T; Kato N; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
J Rheumatol; 2015 Oct; 42(10):1853-60. PubMed ID: 26373560
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis.
Huang L; Shen C; Zhong Y; Ooi JD; Zhou YO; Chen JB; Wu T; Meng T; Xiao Z; Lin W; Ao X; Xiao X; Zhou Q; Xiao P
Clin Exp Med; 2020 May; 20(2):199-206. PubMed ID: 32078076
[TBL] [Abstract][Full Text] [Related]
13. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.
Yang L; Xie H; Liu Z; Chen Y; Wang J; Zhang H; Ge Y; Hu W
BMC Nephrol; 2018 Jun; 19(1):138. PubMed ID: 29902982
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
[TBL] [Abstract][Full Text] [Related]
17. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
Schirmer JH; Wright MN; Herrmann K; Laudien M; Nölle B; Reinhold-Keller E; Bremer JP; Moosig F; Holle JU
Arthritis Rheumatol; 2016 Dec; 68(12):2953-2963. PubMed ID: 27333332
[TBL] [Abstract][Full Text] [Related]
18. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Kronbichler A; Leierer J; Shin JI; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CGM; St Clair EW; Brunetta P; Fervenza FC; Geetha D; Keogh KA; Monach PA; Ytterberg SR; Mayer G; Specks U; Stone JH;
Arthritis Rheumatol; 2019 Nov; 71(11):1888-1893. PubMed ID: 31216123
[TBL] [Abstract][Full Text] [Related]
19. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.
Rhee RL; Hogan SL; Poulton CJ; McGregor JA; Landis JR; Falk RJ; Merkel PA
Arthritis Rheumatol; 2016 Jul; 68(7):1711-20. PubMed ID: 26814428
[TBL] [Abstract][Full Text] [Related]
20. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome.
Wester Trejo MAC; Floßmann O; Westman KW; Höglund P; Hagen EC; Walsh M; Bruijn JA; Jayne DRW; Bajema IM; Berden AE
Rheumatology (Oxford); 2019 Jan; 58(1):103-109. PubMed ID: 30551161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
